Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bristol’s Ixabepilone Granted Priority Review By FDA For Breast Cancer

This article was originally published in The Pink Sheet Daily

Executive Summary

Regulatory action on the epothilone B analog is anticipated in October, Bristol says.

You may also be interested in...



Bristol’s Breast Cancer Treatment Ixempra Gets FDA Nod

Ixempra, part of a new class of antineoplastic chemotherapy agents, is approved as both a monotherapy and in combination with capecitabine.

Bristol’s Breast Cancer Treatment Ixempra Gets FDA Nod

Ixempra, part of a new class of antineoplastic chemotherapy agents, is approved as both a monotherapy and in combination with capecitabine.

Bristol To Submit Ixabepilone In First Half Of 2007 For Metastatic Breast Cancer

Firm reports statistically significant Phase III data for ixabepilone/Xeloda combination at American Society of Clinical Oncology meeting in Chicago.

Related Content

Topics

UsernamePublicRestriction

Register

PS066196

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel